X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1592) 1592
Publication (86) 86
Book Review (43) 43
Newsletter (13) 13
Magazine Article (10) 10
Newspaper Article (8) 8
Book Chapter (4) 4
Conference Proceeding (3) 3
Data Set (1) 1
Reference (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
liraglutide (1293) 1293
humans (1191) 1191
index medicus (1067) 1067
diabetes mellitus, type 2 - drug therapy (883) 883
hypoglycemic agents - therapeutic use (847) 847
type 2 diabetes (628) 628
male (611) 611
endocrinology & metabolism (590) 590
glucagon-like peptide 1 - analogs & derivatives (538) 538
female (523) 523
diabetes (509) 509
glucagon-like peptide 1 - therapeutic use (471) 471
glucagon-like peptide-1 (463) 463
middle aged (424) 424
liraglutide - therapeutic use (393) 393
exenatide (373) 373
animals (317) 317
treatment outcome (305) 305
insulin (300) 300
glucagon (290) 290
glucose (289) 289
aged (284) 284
pharmacology & pharmacy (278) 278
glycemic control (269) 269
diabetes mellitus, type 2 - blood (266) 266
obesity (259) 259
adult (257) 257
metformin (253) 253
peptides - therapeutic use (251) 251
hypoglycemic agents - adverse effects (250) 250
glp-1 (226) 226
venoms - therapeutic use (219) 219
drug therapy (211) 211
analysis (207) 207
diabetes mellitus (207) 207
blood glucose - drug effects (206) 206
care and treatment (205) 205
hypoglycemic agents - administration & dosage (204) 204
hypoglycemic agents - pharmacology (201) 201
safety (197) 197
glucagon-like peptide-1 receptor - agonists (195) 195
blood glucose - metabolism (191) 191
clinical trials (183) 183
diabetes therapy (181) 181
medicine, general & internal (178) 178
double-blind (175) 175
peptides (175) 175
diabetes mellitus, type 2 - complications (174) 174
risk factors (173) 173
internal medicine (167) 167
glucagon-like peptide-1 receptor (166) 166
open-label (164) 164
efficacy (163) 163
diabetes mellitus, type 2 - metabolism (159) 159
incretins - therapeutic use (157) 157
obesity - drug therapy (155) 155
research (155) 155
drug therapy, combination (153) 153
beta-cell function (142) 142
glycated hemoglobin a - metabolism (141) 141
glucagon-like peptide 1 (138) 138
glucagon-like peptide 1 - adverse effects (137) 137
hypoglycemic agents (137) 137
weight loss - drug effects (137) 137
receptors, glucagon - agonists (136) 136
body weight (135) 135
glucagon-like peptide 1 - pharmacology (130) 130
type 2 diabetes mellitus (129) 129
metformin - therapeutic use (128) 128
mice (127) 127
body mass index (125) 125
double-blind method (123) 123
health aspects (123) 123
hypoglycemia (123) 123
glycated hemoglobin a - analysis (121) 121
insulin - therapeutic use (120) 120
liraglutide - pharmacology (120) 120
sitagliptin (120) 120
dipeptidyl-peptidase iv inhibitors - therapeutic use (119) 119
dosage and administration (118) 118
type-2 diabetes-mellitus (118) 118
abridged index medicus (115) 115
dextrose (115) 115
diabetes mellitus, type 2 - physiopathology (113) 113
glucagon-like peptide 1 - administration & dosage (112) 112
hyperglycemia (112) 112
body weight - drug effects (109) 109
mellitus (109) 109
medicine & public health (108) 108
weight loss (107) 107
medicine, research & experimental (105) 105
insulin resistance (103) 103
randomized controlled trials as topic (101) 101
drug administration schedule (100) 100
rats (98) 98
patients (92) 92
glycosylated hemoglobin (91) 91
human glp-1 analog (88) 88
risk (88) 88
therapy (88) 88
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1555) 1555
German (20) 20
Spanish (11) 11
French (9) 9
Czech (6) 6
Italian (6) 6
Japanese (6) 6
Chinese (4) 4
Danish (3) 3
Hungarian (2) 2
Portuguese (2) 2
Croatian (1) 1
Dutch (1) 1
Polish (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Therapeutics, ISSN 0149-2918, 2011, Volume 33, Issue 7, pp. 793 - 811
Journal Article
Journal Article
2017, Topical talks : talks of interest in the biomedical and life sciences
Web Resource
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 7, pp. 1765 - 1779
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
MEDICINE, GENERAL & INTERNAL | IN-VITRO | METFORMIN-TREATED PATIENTS | HEALTHY-SUBJECTS | 2ND-PHASE INSULIN-SECRETION | IMPROVES GLYCEMIC CONTROL | BETA-CELL APOPTOSIS | IV INHIBITOR | 7-36 AMIDE | IMPROVED GLUCOSE-TOLERANCE | EXENATIDE SYNTHETIC EXENDIN-4 | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Care and treatment | Diagnosis | Glucagon | Analysis | Dosage and administration | Research | Protease inhibitors | Drug therapy | Proteins | Diabetes | Kinases | Insulin | Rodents
Journal Article
Journal Article
Diabetes, ISSN 0012-1797, 10/2014, Volume 63, Issue 10, pp. 3346 - 3358
GLP-1 receptor (GLP-1R) is widely located throughout the brain, but the precise molecular mechanisms mediating the actions of GLP-1 and its long-acting analogs... 
NERVOUS-SYSTEM | GLUCOSE-HOMEOSTASIS | ENERGY-EXPENDITURE | GLUCAGON-LIKE PEPTIDE-1 | FOOD-INTAKE | ENDOCRINOLOGY & METABOLISM | WEIGHT-LOSS | RAT-BRAIN | DIET-INDUCED OBESITY | RECEPTORS | TYPE-2 DIABETES-MELLITUS | Protein Kinases - metabolism | Metformin - therapeutic use | Obesity - drug therapy | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Eating - physiology | Young Adult | Glucagon-Like Peptide 1 - agonists | Aged, 80 and over | Adult | Female | Hypothalamus - drug effects | Drug Therapy, Combination | Energy Metabolism - physiology | Hypoglycemic Agents - therapeutic use | Glucagon-Like Peptide 1 - analogs & derivatives | Metformin - pharmacology | Glucagon-Like Peptide 1 - pharmacology | Rats | Hypoglycemic Agents - pharmacology | Obesity - metabolism | Peptides - pharmacology | Eating - drug effects | Animals | Hypothalamus - metabolism | Venoms - therapeutic use | Adipose Tissue, Brown - drug effects | Adipose Tissue, Brown - metabolism | Aged | Mice | Venoms - pharmacology | Thermogenesis - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Energy Metabolism - drug effects | Liraglutide | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Complications and side effects | Thermogenesis | Body weight | Brown adipose tissue | Development and progression | Research | Risk factors
Journal Article